Covenant Health /ID# 223753

Edmonton, Alberta T6K 4B2

0 studies enrolling now · 1 studies all time

What they study most

Crohn's Disease (CD)

Studies at this site

• Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) — Running, not enrolling